Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

The global structural heart devices market is experiencing robust growth, driven by increasing incidences of structural heart diseases, expanded indications for transcatheter products, and a growing ...

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...

Researchers at the NIH and Emory School of Medicine have completed the first minimally invasive coronary artery bypass of the ...

Chris Waddell, a leader for the heart valve replacement business at Abbott, announced on social media that he is leaving the company.

Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to ...

Boston Scientific is acquiring SoniVie, the developer of the catheter-based Tivus intravascular ultrasound system. With a ...